A groundbreaking machine designed to preserve donated lungs outside the body could drastically alter the landscape of organ transplantation in England and Wales. By potentially salvaging up to 80% of currently wasted lungs, this innovation seeks to address the nation’s dismal lung transplant statistics, providing hope to hundreds of patients awaiting vital surgeries.
A Dire Need for Change
The UK’s lung transplant rates rank among the lowest globally. Recent data from NHS Blood and Transplant reveals that 170 individuals, including six children, are on the waiting list for new lungs. The stark reality is that many patients endure lengthy waits for transplants—averaging one to two years—while a significant proportion, nearly 20%, perish within a year of being placed on the list due to the absence of suitable organs.
Currently, a mere 23% of all donated lungs are utilised, with rejection often stemming not only from concerns about organ quality but also from logistical challenges related to staffing and theatre availability. This leaves countless viable organs unused, exacerbating the already critical situation for patients in need.
The XVIVO Perfusion System
In response to this pressing issue, the National Institute for Health and Care Excellence (Nice) has drafted new guidelines advocating for the implementation of the XVIVO perfusion system within the NHS. This initiative proposes a four-year trial to evaluate the machine’s efficacy and cost-effectiveness. The technology is designed to keep donated lungs viable for transplantation by warming them to body temperature, circulating a fluid that mimics blood plasma, and ventilating them to simulate normal breathing. This innovative approach enables medical teams to closely monitor lung function, manage infections, and address any complications that arise during the waiting period.
Dr. Anastasia Chalkidou, the healthtech programme director at Nice, emphasised the importance of this technology, stating, “Every donated lung is a precious gift, and right now too many of them never reach a patient who needs them. This technology has the potential to change that, giving transplant teams the time and information they need to make the most of organs that would otherwise go unused.”
A Collaborative Effort for Better Outcomes
The draft guidance from Nice aims to democratise access to this technology, ensuring that all transplant centres—regardless of size or geographical location—can benefit from its implementation. Jonathan Blades, head of policy at Asthma + Lung UK, highlighted the urgency of this initiative: “Lung transplant rates in the UK remain lower than in many other developed countries, while respiratory health outcomes remain the worst in Europe. Renewed political and research focus is needed to transform lung health in the UK, and this new technology marks an important step towards that ambition.”
Medical professionals are optimistic about the potential impact of the XVIVO system. Professor Andrew Fisher, a consultant transplant physician at Newcastle upon Tyne hospitals NHS foundation trust, stated, “It’s important that robust evidence is generated that shows exactly how much impact the use of this device has on lung transplant activity and supports timely access to transplant for patients desperately waiting for a suitable organ.”
Why it Matters
The introduction of the XVIVO perfusion system represents a pivotal moment for lung transplantation in the UK, where the current system fails to meet the needs of patients. By potentially increasing the number of usable lungs and reducing waste, this technology holds the promise of saving lives and alleviating the burden on individuals and families affected by severe lung conditions. As the NHS continues to grapple with the challenges of organ donation and transplantation, innovations like this may pave the way for a more effective and equitable healthcare system, ensuring that every potential donor organ is given a chance to help those in dire need.
